{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-076352","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2026-06-22T20:01:26+00:00","discovered_at":"2026-06-22T20:02:01.565014+00:00","generated_at":"2026-06-22T20:02:30.569727+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"ArriVent BioPharma announces 2026 annual meeting voting results; directors elected, auditor ratified","bullets":["Stockholders elected James Healy, John Hohneker, and Stuart Lutzker as Class II directors for three-year terms.","Healy received 18,058,285 votes for; Hohneker 28,043,164; Lutzker 29,495,923; broker non-votes 3,832,858 each.","Ratification of PricewaterhouseCoopers LLP as auditor for FY 2026 passed with 33,411,773 votes for, 829 against.","Quorum of 33,418,793 shares (72.07% of eligible) was present at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-076352","json":"https://secwatch.observer/filing/0001104659-26-076352.json","markdown":"https://secwatch.observer/filing/0001104659-26-076352.md","text":"https://secwatch.observer/filing/0001104659-26-076352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926076352/0001104659-26-076352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926076352/tm2618466d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T20:02:30.569727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01bc8700d626bdc0c78ec1fe4e6d4c8e12b85407","claim":"ArriVent BioPharma, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.","evidence_excerpt":"1. Election of Directors Nominee Shares Voted For Shares Voted to Withhold Authority Broker Non-votes James Healy, M.D., Ph.D. 18,058,285 11,527,650 3,832,858 John Hohneker, M.D. 28,043,164 1,542,771 3,832,858 Stuart Lutzker, M.D., Ph.D. 29,495,923 90,012 3,832,858","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926076352/0001104659-26-076352-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"},{"claim_id":"9de22d4a3cf303f22656d9b036a7ebe410f71cfa","claim":"ArriVent BioPharma, Inc. shareholders approved Auditor Ratification at the 2026-06-18 meeting.","evidence_excerpt":"2. Auditor Ratification Shares Voted For Shares Voted Against Shares Abstaining Broker Non-votes 33,411,773 829 6,191 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926076352/0001104659-26-076352-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}